Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, announces the initiation of its Venous Leg Ulcer (VLU) scientific expert group. This initiative is an important step towards the planning and execution of the Phase 2 clinical trial of AUP-16 for Venous Leg Ulcers (VLUs).
The VLU scientific expert group was established during the European Wound Management Association (EWMA) Conference, held in Milan. Esteemed Key Opinion Leaders (KOLs) contributing their expertise to this group include Kirsi Isoherranen, from Helsinki University Hospital, Finland, recently appointed President of the European Wound Management Association; Joachim Dissemond, from University of Essen, Germany; Arkadiusz Jawień, from Nicolaus Copernicus University, Bydgoszcz, Poland; and Valentina Dini, from University of Pisa, Italy. Aurealis Therapeutics is honored and grateful for the collaboration with these world-renowned professionals.
The first meeting of the VLU scientific expert group was on September 19, 2023. During this session, the group discussed treatment gaps, unmet medical needs, and potential strategies to guide the AUP-16 VLU Phase 2 clinical trial.
Laurent Décory, Chief Operating Officer at Aurealis Therapeutics, expressed his enthusiasm for this collaborative effort, stating, “Our partnership with the esteemed members of the VLU scientific expert group shows our dedication to developing innovative treatments and advancing the management of chronic, non-healing wounds. Together, we are creating a path to enhance the lives of those suffering from Venous Leg Ulcers. This scientific expert group is an important step towards bringing AUP-16 closer to its second Phase 2 clinical trial, and we are honored to work with such a renowned group of experts.”
AUP-16 is a genetically engineered Lactococcus Cremoris, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF2, bFGF), interleukin-4 (IL4) and macrophage colony stimulating factor (CSF1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers and pressure ulcers). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage synthetic biology company creating bacteria-based multi-factor cell and gene therapies for chronic wounds and cancer. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Laurent Décory, COO